Aibios, a Tokyo-based biotechnology company founded in 2015, specializes in the development of immunotherapeutics for a range of diseases including inflammatory bowel disease (IBD), neuroinflammatory disease, chronic obstructive pulmonary disease (COPD), and emphysema. Their innovative small molecules modulate both the innate and adaptive immune system, targeting macrophages and T cells to provide therapeutic solutions for gastroenterology, respiratory, and neurological diseases. With a focus on research and development, Aibios aims to make significant advancements in the fields of immunology, oncology, and neuroscience.